EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab
New indication concerns their combination in the first-line treatment of adult patients with unresectable malignant pleural mesothelioma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Sacituzumab Govitecan Prolongs Survival in Relapsed or Refractory Metastatic Triple Negative Breast Cancer
Primary results of the ASCENT study
EMA Recommends Extension of Therapeutic Indications for Osimertinib
New indication concerns adjuvant treatment in patients with NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
FDA also approved the VENTANA MMR RxDx Panel as a companion diagnostic device for patient selection
Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to Elective Neck Dissection in Early Oral Cancer
Non inferiority demonstrated in terms of the survival rate and superiority shown in terms of neck functionality
Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations
Results from the KO-TIP-001 study with farnesyltransferase inhibitor in patients with head and neck squamous cell carcinoma
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
Evidence for efficacy is based on the results from the HORIZON study
FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer and Oesophageal Adenocarcinoma
Evidence for efficacy is based on the results from the CHECKMATE-649 study
The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic Assessment in Metastatic Non-Seminomatous Germ Cell Tumours
It includes age and lung metastases as additional adverse prognostic factors and uses a single cut-off of LDH at 2.5× ULN
Percentage of Cancer Patients Who Are Eligible for and Respond to Genome-Targeted Therapy Modestly Increased Over Time
A new analysis from US show that response to genome-targeted therapy increased from 2.73% in 2006 to 7.04% in 2020
FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer
Evidence for efficacy and safety is based on the results from the TROPHY study
FDA Approves New Dosing Regimen for Cetuximab
Approval is based on population pharmacokinetic modelling analyses